US Stock MarketDetailed Quotes
LYRA Lyra Therapeutics
- 0.192
- -0.007-3.28%
Trading Nov 27 14:40 ET
12.55MMarket Cap-128P/E (TTM)
0.207High0.188Low812.70KVolume0.192Open0.198Pre Close160.80KTurnover1.95%Turnover RatioLossP/E (Static)65.46MShares6.79052wk High0.61P/B8.00MFloat Cap0.16352wk Low--Dividend TTM41.71MShs Float22.000Historical High--Div YieldTTM9.38%Amplitude0.163Historical Low0.197Avg Price1Lot Size
Lyra Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -14.94%-16.22M | -39.90%-19.98M | -41.67%-22.46M | -45.91%-63.3M | -56.68%-19.06M | -30.13%-14.11M | -68.62%-14.28M | -33.14%-15.85M | -68.03%-43.39M | -7.67%-12.16M |
| Net income from continuing operations | 24.14%-11.87M | -208.18%-48.13M | -38.12%-22.45M | -13.39%-62.68M | -6.47%-15.16M | -5.99%-15.65M | -8.72%-15.62M | -36.47%-16.26M | -27.04%-55.28M | -4.54%-14.24M |
| Depreciation and amortization | 157.35%39K | 730.43%145K | -52.11%136K | -73.95%278K | -61.71%85K | -124.37%-68K | -108.04%-23K | 1.43%284K | 6.59%1.07M | -20.14%222K |
| Change In working capital | -549.10%-5.48M | 380.65%2.7M | -79.29%-1.37M | -207.24%-4.89M | -498.50%-4.38M | -35.86%1.22M | -121.34%-961K | 31.75%-763K | -67.28%4.56M | -158.10%-732K |
| -Change in prepaid assets | -54.56%-881K | 32.88%388K | -130.49%-257K | 213.48%867K | 151.01%302K | 40.63%-570K | -29.98%292K | 127.22%843K | 9.80%-764K | -201.37%-592K |
| -Change in payables and accrued expense | -277.15%-5.49M | -32.82%-951K | -72.67%267K | -17.79%1.94M | -396.15%-1.42M | 0.65%3.1M | -325.16%-716K | 230.27%977K | -34.31%2.36M | -119.58%-286K |
| -Change in other current assets | 178.67%343K | 391.98%1.59M | 87.50%-256K | -241.68%-4.93M | -97.36%-2.77M | -205.31%-436K | 173.64%324K | -14,528.57%-2.05M | -423.32%-1.44M | -441.31%-1.4M |
| -Change in other current liabilities | 326.14%744K | 661.79%2.26M | -372.00%-590K | -258.32%-1.21M | -122.51%-351K | -20.96%-329K | -50.94%-403K | 51.36%-125K | 177.38%763K | 711.37%1.56M |
| -Change in other working capital | 64.15%-195K | -30.57%-598K | -29.76%-532K | -142.84%-1.56M | -1,227.27%-146K | -51.53%-544K | 12.76%-458K | -109.05%-410K | -68.95%3.64M | 95.94%-11K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -14.94%-16.22M | -39.90%-19.98M | -41.67%-22.46M | -45.91%-63.3M | -56.68%-19.06M | -30.13%-14.11M | -68.62%-14.28M | -33.14%-15.85M | -68.03%-43.39M | -7.67%-12.16M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 154.35%8.14M | 6,548.48%36.18M | 47.83%7.86M | 80.64%-12.58M | 96.36%-2.36M | -51,551.72%-14.98M | -3,907.14%-561K | 5,815.05%5.32M | -1,820.41%-65.01M | -5,889.84%-64.87M |
| Net PPE purchase and sale | 64.58%-51K | -176.06%-196K | -4,675.56%-2.15M | -538.41%-1.05M | -2,710.71%-787K | -396.55%-144K | -407.14%-71K | 51.61%-45K | 95.16%-164K | 97.41%-28K |
| Net investment purchase and sale | 155.22%8.19M | 7,522.86%36.37M | 86.68%10.01M | 82.21%-11.54M | 97.58%-1.57M | ---14.84M | ---490K | --5.36M | ---64.84M | ---64.84M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 154.35%8.14M | 6,548.48%36.18M | 47.83%7.86M | 80.64%-12.58M | 96.36%-2.36M | -51,551.72%-14.98M | -3,907.14%-561K | 5,815.05%5.32M | -1,820.41%-65.01M | -5,889.84%-64.87M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 94.50%-23K | -100.19%-89K | 216,000.00%8.64M | -31.75%65.69M | 18.92M | -77.12%-418K | -51.10%47.19M | -33.33%4K | 26,712.53%96.26M | 0 |
| Net common stock issuance | --0 | ---- | ---- | -31.10%69.24M | --19.24M | --0 | ---- | ---- | --100.5M | --0 |
| Net preferred stock issuance | ---- | ---- | --8.81M | ---- | ---- | ---- | ---- | --0 | ---- | ---- |
| Proceeds from stock option exercised by employees | --0 | --0 | -25.00%3K | 1,187.50%103K | --0 | --2K | --97K | -50.00%4K | -98.68%8K | --0 |
| Net other financing activities | 94.52%-23K | ---98K | ---169K | 13.94%-3.65M | ---322K | -77.97%-420K | ---- | ---- | -1,633.06%-4.25M | --0 |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 94.50%-23K | -100.19%-89K | 216,000.00%8.64M | -31.75%65.69M | --18.92M | -77.12%-418K | -51.10%47.19M | -33.33%4K | 26,712.53%96.26M | --0 |
| Net cash flow | ||||||||||
| Beginning cash position | -39.20%33.9M | -24.01%17.79M | -30.04%23.75M | -26.33%33.94M | -76.35%26.24M | -54.33%55.75M | -31.31%23.41M | -26.33%33.94M | -38.50%46.08M | 89.83%110.98M |
| Current changes in cash | 72.54%-8.11M | -50.20%16.11M | 43.46%-5.95M | 15.96%-10.2M | 96.76%-2.5M | -165.60%-29.51M | -63.25%32.34M | 12.18%-10.53M | 57.94%-12.13M | -522.04%-77.03M |
| End cash Position | -1.71%25.79M | -39.20%33.9M | -24.01%17.79M | -30.04%23.75M | -30.04%23.75M | -76.35%26.24M | -54.33%55.75M | -31.31%23.41M | -26.33%33.94M | -26.33%33.94M |
| Free cash flow | -14.14%-16.27M | -40.58%-20.18M | -54.79%-24.6M | -47.77%-64.35M | -62.77%-19.85M | -31.11%-14.26M | -69.18%-14.35M | -32.48%-15.9M | -49.11%-43.55M | 1.52%-12.19M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data